Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.63 |
| ▸ | DRD3 | P35462 | 10/20 | 0.63 |
| ▸ | DRD4 | P21917 | 9/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3380835 | 0.87 | DRD2 (0.62) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL3118886 | 0.87 | DRD2 (0.62) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL3120754 | 0.85 | DRD2 (0.67) | DRD2DRD3DRD4HTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL6709052 | 0.85 | DRD2 (0.66) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL3122150 | 0.83 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| SCHEMBL14006049 | 0.82 | DRD2 (0.66) | DRD2DRD3DRD4 | |
| SCHEMBL14006129 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL14006056 | 0.79 | DRD2 (0.65) | DRD2DRD3DRD4HTR1AADRA1D | |
| SCHEMBL1460505 | 0.78 | DRD2 (0.83) | DRD2DRD3DRD4HTR1A | |
| SCHEMBL6053607 | 0.78 | DRD2 (0.94) | DRD2DRD3DRD4HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | claimed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | claimed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | claimed |
| US-9023656-B2 | Reactive mass labels | ELECTROPHORETICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| EP-1907860-B1 | MASS LABELS | ELECTROPHORETICS LTD (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20100178710-A1 | Mass Labels | ELECTROPHORETICS LIMITED (GB) | 2010-07-15 | — | — | US | disclosed |
| EP-1907860-A2 | MASS LABELS | Electrophoretics Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007012849-A2 | MASS LABELS FOR BIOMOLECULES CONTAINING A 2,6-DIMETHYL-PIPERIDIN-l-YL METHYLENE OR A PYRIMIDIN-2-YL THIOMETHYLENE MASS MARKER MOIETY AND A SUCCINIMID-OXY-CARBONYL REACTIVE FUNCTIONAL GROUP | ELECTROPHORETICS LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178710-A1 | Mass Labels | B2M, SRRM2, CCNB1 | DRD2 3923/4885DRD3 2912/4885DRD4 3928/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | DRD2 1008/4885DRD3 1137/4885DRD4 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.